Therapeutic Drug Monitoring of Posaconazole: an Update |
| |
| Authors: | Bart G. J. Dekkers Martijn Bakker Kim C. M. van der Elst Marieke G. G. Sturkenboom Anette Veringa Lambert F. R. Span Jan-Willem C. Alffenaar |
| |
| Affiliation: | 1.Department of Clinical Pharmacy and Pharmacology,University of Groningen, University Medical Center Groningen,Groningen,The Netherlands;2.Department of Hematology,University of Groningen, University Medical Center Groningen,Groningen,The Netherlands;3.Department of Clinical Pharmacy,ZGT Hospital Group Twente,Hengelo,The Netherlands |
| |
| Abstract: | Posaconazole is a second-generation triazole agent with a potent and broad antifungal activity. In addition to the oral suspension, a delayed-release tablet and intravenous formulation with improved pharmacokinetic properties have been introduced recently. Due to the large interindividual and intraindividual variation in bioavailability and drug-drug interactions, therapeutic drug monitoring (TDM) is advised to ensure adequate exposure and improve clinical response for posaconazole. Here, we highlight and discuss the most recent findings on pharmacokinetics and pharmacodynamics of posaconazole in the setting of prophylaxis and treatment of fungal infections and refer to the challenges associated with TDM of posaconazole. |
| |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ |
|
